Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation

NCT05307705 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05307705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05307705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 11, 2022
Completion date
December 31, 2026
Enrollment
260 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer